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Changes in mRNA expression levels of solute carrier
transporters in inflammatory bowel disease patients
Abstract
Inflammatory bowel disease (IBD) is an inflammatory condition that affects gastrointestinal tract. Solute
carrier superfamilly of transporters (SLC) comprise proteins involved in the uptake of drugs, hormones,
and other biologically active compounds. The purpose of this study was to determine the mRNA
expression levels of 15 solute carrier transporters in two regions of the intestine in IBD patients.
Endoscopic biopsies were taken from two locations (terminal ileum and colon) for histological
examination and RNA extraction. We quantitatively measured the mRNA expression of 15 SLC
transporters in 107 IBD patients (53 Crohn's disease and 54 ulcerative colitis) and 23 control subjects.
Messenger RNA expression was evaluated using the quantitative reverse transciption-PCR technique.
We observed that in ileum of IBD patients, mRNA levels for SERT, ENT1, ENT2, and OATP2B1 were
significantly elevated while for ASBT and OCTN2 they were significantly lower. In colon, mRNA
levels for ENT1, ENT2, CNT2, OATP2B1, and OATP4A1 were significantly higher, while mRNA
levels for OCTN2 were significantly decreased. In inflamed colon of IBD patients the mRNA
expression levels of ENT1, ENT2, CNT2, OATP2B1, OATP4A1, and PEPT1 were significantly higher.
We conclude that intestinal SLC mRNA levels are dysregulated in IBD patients, which may be linked to
the inflammation of the tissue and provides an indication about the role of inflammatory signalling in
regulation of SLC expression.
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Abstract 
 
Inflammatory bowel disease (IBD) is an inflammatory condition that affects 
gastrointestinal tract. Solute carrier superfamilly of transporters (SLC) comprise 
proteins involved in the uptake of drugs, hormones, and other biologically active 
compounds. The purpose of this study was to determine the mRNA expression levels 
of 15 solute carrier transporters in two regions of the intestine in IBD patients. 
Endoscopic biopsies were taken from two locations (terminal ileum and colon) for 
histological examination and RNA extraction. We quantitatively measured the mRNA 
expression of 15 SLC transporters in 107 IBD patients (53 Crohn's disease and 54 
ulcerative colitis) and 23 control subjects. Messenger RNA expression was evaluated 
using the quantitative reverse transciption-PCR technique. We observed that in ileum 
of IBD patients, mRNA levels for SERT, ENT1, ENT2, and OATP2B1 were 
significantly elevated while for ASBT and OCTN2 they were significantly lower. In 
colon, mRNA levels for ENT1, ENT2, CNT2, OATP2B1, and OATP4A1 were 
significantly higher, while mRNA levels for OCTN2 were significantly decreased. In 
inflamed colon of IBD patients the mRNA expression levels of ENT1, ENT2, CNT2, 
OATP2B1, OATP4A1, and PEPT1 were significantly higher. We conclude that 
intestinal SLC mRNA levels are dysregulated in IBD patients, which may be linked to 
the inflammation of the tissue and provides an indication about the role of 
inflammatory signalling in regulation of SLC expression. 
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Introduction 
 
Solute carrier superfamily of transporters (SLC) consists of over 300 members 
subdivided into 47 families. They are expressed in most tissues, but primarily in the 
liver, lung, kidney, and intestine. Most solute carrier transporters are localized at 
either basolateral or apical plasma membrane of polarized cells, but some are 
expressed in mitochondria and other organelles. The expression levels of SLCs are 
modulated by cytokines, hormones, growth factors, extracellular signals, and 
changes in the metabolic state of the cell. Typical SLC transporters consist of several 
transmembrane α-helices connected by intra- and extracellular loops and function as 
either monomers or hetero- or homodimers. SLC transporters are responsible for the 
uptake of amino acids, peptides, ions, xenobiotics, drugs, and other biologically 
active compounds (Koepsell et al., 2007). The driving force of SLCs is mostly ion-
dependent, but some of them function as equilibrative transporters. 
 Inflammatory bowel disease (IBD) is a disease affecting the inner lining of the 
gut and it can be divided into two entities: Crohn’s disease (CD) and ulcerative colitis 
(UC). Until now, there are only a few studies implicating the involvement of SLC 
family members in the pathophysiology of IBD and/or other inflammatory conditions. 
For example, the expression and activity of the peptide transporter 1 (PEPT1; gene 
symbol SLC15A1) has been shown to be increased by pro-inflammatory cytokines, 
such as tumour necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) (Vavricka et al., 
2006). This observation was proposed to be linked with the PEPT1-mediated uptake 
of muramyl dipeptide, a degradation product of bacterial outer wall, followed by 
activation of the intracellular receptor NOD1 and consequently of the transcription 
factor NF-ĸB. PEPT1 was also reported to be involved in the suppression of 
inflammation in mouse models of colitis due to the uptake of the therapeutic tripeptide 
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KPV (Dalmasso et al., 2008). Another SLC transporter implicated in IBD is the 
organic cation/zwitterion transporter 2 (OCTN2; gene symbol SLC22A5). It has been 
reported that SLC22As are high susceptibility genes in IBD, located at the so-called 
IBD locus 5 (IBD5), and that genetic polymorphisms within this region contribute to 
the inflammatory phenotype (Cucchiara et al., 2007; Silverberg et al., 2007; Waller et 
al., 2006). These observations are consistent with a mouse study showing that 
homozygous inactivation of Octn2 resulted in spontaneous development of colitis 
(Shekhawat et al., 2007). Decreased expression of Octn2 and another carnitine 
transporter Atb0+ were also shown to be associated with development of 
inflammatory condition in rats (D’Argenio et al., 2006). Recently, the mRNA 
expression levels of OCTN1 and OCTN2 were reported to be significantly decreased 
in UC patients (Noble et al., 2008). Another SLC member implicated in pathogenesis 
of IBD is the apical sodium-dependent bile acid transporter (ASBT; gene symbol 
SLC10A2). It has been shown that the protein levels of this transporter are lower in 
CD patients than in control individuals (Jung et al., 2004). It has been proposed that 
ASBT mRNA levels are decreased by pro-inflammatory cytokines via a mechanism 
that involves the c-Fos transcription factor in human, rat, and mouse intestinal 
epithelium (Neimark et al., 2006). In addition, the expression and function of another 
SLC superfamily member, serotonin transporter (SERT; gene symbol SLC6A4), is 
affected by 2,4,6-trinitrobenzenesulfonic acid (TNBS) -induced inflammation in mice 
(Linden et al., 2005). In concert with this, it has been reported that function and 
expression of SERT are decreased by the pro-inflammatory cytokines TNF-α and 
IFN-γ in human intestine-derived cells (Foley et al., 2007). These observations 
suggest that certain SLC transporters are affected in inflammatory conditions, such 
as IBD. Given the physiological function of SLCs they might contribute to the 
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pathology of this disease, or their function may be affected as a consequence of 
inflammation. 
 Recently, we have described the distribution of 15 SLC transporters along the 
human intestinal tract (Meier et al., 2007). This group included PEPT1, OCTN1, and 
OCTN2, the concentrative nucleoside transporters (CNTs; gene family SLC28), 
ASBT, the organic anion transporting polypeptides (OATPs; gene family SLCO), the 
equilibrative nucleoside transporters (ENTs; gene family SLC29), the organic cation 
transporter 1 (OCT1; gene symbol SLC22A1), the organic anion transporter 2 (OAT2; 
gene symbol SLC22A7), and SERT. In the present study we have determined the 
expression levels of these 15 SLC transporters in terminal ileum and colon of IBD 
patients, in comparison with non-IBD control patients. Localisation, function, and 
implicated association with IBD of these transporters are summarized in Table 1. 
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Materials and Methods 
 
Patients and colonoscopy 
 In this study, 53 patients with ulcerative colitis (UC) and 49 patients with 
Crohn`s Disease (CD), as well as 23 control subjects were enrolled after having 
given their informed consent. Diagnosis of patients with UC and CD was based on 
clinical history, laboratory findings, as well as endoscopic and histological criteria. 
Tissue biopsies were sampled by experienced gastroenterologists. From patients 
with active disease (newly diagnosed patients and patients with refractory disease) 
biopsies were taken both from the inflamed and from the unaffected region (paired 
biopsies). Unaffected areas were defined as mucosa regions without any 
macroscopic/endoscopic signs of inflammation (ulceration, edema, discoloration, 
hemorrhagic appearance, or mucinous/fibrinous coating); these biopsies were 
obtained at least 10-15 cm distant from the inflamed area. Control subjects had an 
indication for a gastrointestinal tract endoscopy for reasons not related to IBD. Biopsy 
specimens were obtained during routine endoscopy, submerged in RNAlater solution 
(Ambion, Austin, USA) and stored at –80°C until further processing. The summary of 
patients' characteristics is presented in Table 2. Additional patient information is 
shown in supplementary material (supplementary tables 1 and 2). 
 
Isolation of RNA from biopsies 
 For RNA isolation from biopsies obtained from IBD patients, intestinal biopsies 
were homogenized for 30 seconds (Polytron PT 2100, Kinematika AG, Switzerland) 
and RNA was extracted using the RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany) 
following the instructions provided by the manufacturer. Control biopsies were 
syringed in TRIzol reagent and RNA was extracted in according to the manufacturer’s 
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protocol (Invitrogen, Carlsbad, USA). RNA was quantified with a GeneQuant 
spectrophotometer (Pharmacia, Uppsala, Sweden) and NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies, Wilmington, USA) 
 
Synthesis of cDNA and quantitative real-time PCR 
 Complementary DNA (cDNA) was produced using the reverse transcription kit 
(Promega, Madison, USA) with 1.2 μg RNA as a template and random hexamers as 
primers. The product was diluted with H2O to a total volume of 120 μl. For each PCR 
reaction 2 µl of the cDNA was used in the final reaction volume of 10 µl. SLC 
expression levels were determined by TaqMan real-time PCR and absolute 
quantification. The cycling conditions were identical to those used in our previous 
study: stage 1 (50°C, 2min); stage 2 (95°C, 10min); stage 3: 40 repeats (95°C, 15s; 
60°C, 1min). Based on our previous observations, for detectable targets each PCR 
was performed in duplicate, for targets below detection limit PCR was performed as a 
single measurement. PCR for villin was performed in triplicate. For each assay, a 
dilution series (12; 120; 1'200; 12'000; 120'000, and 12'000'000 copies) of the cloned 
PCR product was quantified in parallel. The expression levels of the target genes in 
each sample were determined by the ratio of cDNA copies of a target gene vs. cDNA 
copies of villin. The samples below the cut-off limit (<0.01 ratio of target cDNA copies 
vs. villin cDNA copies) were considered undetectable. All the TaqMan Gene 
Expression Assays (Applied Biosystems, Foster City, USA) used in this study were 
the same as used in our previous study (Meier et al., 2007). 
 
Statistical analysis 
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 Basic statistical analysis was performed using the GraphPad Prism 5 software. 
Statistical significance of the differences in mRNA expression levels between the 
patient subgroups was determined by performing ANOVA analysis (Kruskal-Wallis 
test) with Dunn’s Multi Comparison Test. For paired biopsies analysis statistical 
significance was determined using a paired t-test. The effect of steroid therapy, age, 
gender, and smoking on expression levels was analyzed using mixed models of 
ANOVA with patients as random factors. Here, the values of mRNA expression levels 
were logarithmically transformed prior to an analysis performed using SPSS 13 
(SPSS Inc., Chicago, USA) (supplementary table 3). 
 
Ethical considerations 
 
 The study protocol and consent forms were approved by the State Ethical 
Committee of Basel (EKBB) and University Hospital Zurich (EK-837) prior to the start 
of the study. The sample collection was carried out at the University Hospital Basel 
and the University Hospital Zurich between 2001 and 2007. 
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Results 
 
The mRNA expression of SLC transporters in terminal ileum of IBD patients 
 Despite considerable individual variation between patients within each 
subgroup, we observed clear and significant differences in SLC mRNA expression 
levels in IBD patients compared to the control group. We found that in terminal ileum, 
mRNA expression levels of ASBT and OCTN2 were significantly decreased in IBD 
patients (Table 3). Also the mRNA expression levels of CNT2 were decreased in IBD 
patients, but it was not statistically significant. The elevation of mRNA levels of 
SERT, ENT1, ENT2, and OATP2B1 in ileum of IBD patients was statistically 
significant, but the increase in mRNA levels of PEPT1 and OCTN1 was not. The 
increase in the expression levels of CNT1 was only significant in CD patients. We 
observed statistically significant elevation of mRNA expression of OATP4A1, but its 
levels in IBD patients remained on the border of detection limit. The mRNA levels of 
CNT3, OAT2, OATP1A2, and OCT1 were below detection limit. 
 
The mRNA expression of SLC transporters in colon of IBD patients 
 In colon, we observed that OCTN2 mRNA levels were significantly decreased 
in IBD patients (Table 3). The mRNA levels of ENT1, ENT2, OATP2B1, OATP4A1, 
and CNT2 were significantly increased, while the increase in the mRNA expression of 
OCTN1 was statistically significant only in UC patients, and the increase of mRNA 
expression levels of PEPT1 was significant only in CD patients. The mRNA levels of 
ASBT, SERT, CNT1, CNT3, OAT2, and OATP1A2 in colon of IBD patients were 
below detection limit. The OCT1 mRNA was detected, but its levels were not altered 
in IBD patients. Among 15 targets tested, only two exhibited significant differences 
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between CD and UC patients, namely OATP2B1 and OATP4A1. Both OATP2B1 and 
OATP4A1 expression were higher in UC patients. 
 
Changes in mRNA expression levels of SLC transporters in inflamed tissues of 
CD patients 
 Analysis of the biopsies based on the inflammatory status of the tissue 
revealed that changes in mRNA expression levels of certain SLC transporters in CD 
patients were correlated with the inflammation (Fig. 1). In terminal ileum, expression 
levels of ENT1 and ENT2 in the inflamed tissues were higher than in non-inflamed 
tissues, but this difference was not statistically significant (Fig. 1A). The mRNA 
expression levels of OATP2B1 and OATP4A1 were not changed, while the 
expression of CNT2 was decreased, but not significantly. To exclude the influence of 
individual variation in basal mRNA levels of SLC transporters we next analysed only 
paired biopsies from terminal ileum of CD patients. We observed that the increase in 
mRNA expression levels of ENT2, and OATP2B1 between the non-inflamed and 
inflamed tissues became significant (Fig. 1B). The changes in mRNA expression 
levels of ENT1, OATP4A1, and CNT2 were still apparent, but did not reach statistical 
significance in paired samples. Similarly, compared to non-inflamed tissues mRNA 
levels of ENT1, ENT2, CNT2, OATP2B1, OATP4A1, and PEPT1 were higher, but not 
significantly, in the inflamed colonic tissues of all CD patients (Fig. 1C). The 
expression levels of OCTN1 and OCTN2 were not changed upon inflammation. 
When only paired biopsies were analysed, the mRNA levels of ENT2, OATP2B1, and 
PEPT1 were significantly increased in colon of CD patients. Interestingly, we 
observed a significant increase in mRNA levels of OCTN1, but not OCTN2, when 
only paired biopsies were included in the analysis. The mRNA levels of ENT1, CNT2, 
and OATP4A1 were increased, but not significantly (Fig. 1D). 
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Changes in mRNA expression levels of SLC transporters in inflamed colon of 
UC patients 
 In colon of UC patients, the inflamed tissues expressed significantly higher 
mRNA levels of ENT1, ENT2, CNT2, OATP4A1, and PEPT1. Similarly to the colon of 
CD patients, the levels of OCTN1 and OCTN2 in UC patients were not changed upon 
inflammation (Fig. 2A). When paired biopsies were analysed, the mRNA levels of 
ENT1, ENT2, CNT2, OATP2B1, OATP4A1, and OCTN1 were significantly higher. 
Despite the strong increase tendency, the elevation of the mRNA levels of PEPT1 in 
inflamed tissue did not reach statistical significance, when paired biopsies were 
analyzed (Fig. 2B).  
 
Changes in mRNA expression levels of SLC transporters in IBD patients on 
steroid therapy 
 Next, we examined, whether SLC mRNA levels in IBD patients were 
influenced by any medication taken. We found a strong correlation between colonic 
mRNA expression levels of OCTN2 and steroid therapy in male patients (Table 4): 
we observed approximately 2.5-fold increase in OCTN2 expression in both CD (from 
0.02 to 0.05) and UC (from 0.04 to 0.09) in male patients. Also, in CD males, steroid 
therapy decreased mRNA levels of ASBT in terminal ileum, but this was not 
statistically significant. The mRNA levels of OATP4A1 in UC patients taking steroids 
were increased 2-fold, but this change was not statistically significant. All the 
changes in mRNA expression levels of SLCs in IBD patients taking steroids are 
summarized in Table 4. 
DMD 27367 
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Discussion 
 
 SLC transporters play an important role in the absorption of drugs and 
biologically active compounds in the intestine. Determining expression levels of SLC 
transporters in IBD intestine provides an indication about the role of inflammatory 
signalling cascades on regulation of SLC expression. Since we did not observe any 
significant gender- or age-dependent changes in mRNA expression levels in either of 
two intestinal regions of IBD patients (supplementary table 3), we propose that these 
differences in mRNA expression levels may be attributed to inflammation and/or 
therapy. We observed certain small, but significant, differences in the expression 
levels of some SLCs in both regions of control group, compared to the control levels 
reported in our previous study (Meier et al., 2007). Significant differences in mRNA 
levels were detected for four out of nine detectable target genes in terminal ileum 
(PEPT1, ASBT, CNT1, and CNT2) and three out of nine detectable target genes in 
colon (OCT1, CNT2, and ENT2). These differences may derive from individual 
variation in mRNA levels of these transporters amongst the patients in each 
subgroup, and be dependent on variables such as individual differences in 
medication. 
 We observed significantly decreased ASBT mRNA levels in IBD patients - an 
observation that has previously been reported for CD patients at the ASBT protein 
level (Jung et al., 2004). Although we did not observe any changes in ASBT mRNA 
levels in the inflamed tissues, steroid therapy seems to be associated with a 
tendency of decreased ASBT mRNA levels in terminal ileum of male CD patients. 
This is in apparent disagreement with the previous observation that CD patients 
undergoing steroid treatment exhibit increased levels of ASBT (Jung et al, 2004). 
This contradiction may be explained by the small numbers of patients employed in 
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the previous study, and larger heterogeneity of the dose- and time-dependent 
treatment of IBD population tested in the present study. 
 We also observed a significant decrease in mRNA levels of the carnitine 
transporter OCTN2 in IBD patients. The OCTN2 protein is encoded by the IBD5 locus 
and polymorphisms in the SLC22A5 coding regions have been linked to IBD 
pathology (Cucchiara et al., 2007; Silverberg et al., 2007; Waller et al., 2006; Russell 
et al., 2006). In rats, a decrease in Octn2 expression levels triggers inflammation of 
the gastrointestinal tract (Shekhawat et al., 2007), possibly due to an aberration of 
carnitine transport and fatty acid metabolism (D’Argenio et al., 2006). Interestingly, a 
decrease in mRNA expression of OCTN2 was recently reported in sigmoid region of 
UC colon (Noble et al., 2008), although to a lesser extent than to the decrease 
observed here in colon and terminal ileum (Table 3). Low levels of OCTN2 even in 
non-inflamed tissues from IBD patients could result from either specific genetic 
background, e.g. polymorphisms/mutations in OCTN2 gene and/or its promoter 
sequence, or it could be due to suppression by circulating pro-inflammatory 
cytokines. Interestingly, we observed a slight, but not statistically significant decrease 
in OCTN2 mRNA levels in all inflamed tissues compared to all non-inflamed biopsies 
(Fig. 1C and Fig. 2A). Moreover, a closer examination of paired biopsies reveals that 
50% of CD patients, and 82% of UC patients, express lower mRNA levels of OCTN2 
in paired inflamed tissues (data not shown). In addition, we demonstrated higher 
mRNA expression levels of OCTN2 in patients taking steroids (Table 4). Moreover, in 
patients in remission of the disease, colonic OCTN2 mRNA levels of were slightly, 
but not significantly, higher than in non-remission CD patients (data not shown) 
suggesting that elevation of the mRNA levels of OCTN2 might be correlated with 
overall therapeutic effect. All these observations support the idea of OCTN2 being 
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associated with IBD and/or inflammation. The exact mechanisms, by which the 
OCTN2 protein contributes to the pathogenesis of IBD, remain unclear. 
 We observed an increase in mRNA levels of most intestinal nucleoside 
transporters in colon and in terminal ileum. It has been reported that altered 
expression levels of certain nucleoside transporters are associated with pathological 
states, such as ampullary cancer (Santini et al., 2008) and HIV infection (Guallar et 
al., 2007). The relevance of the observed increase in nucleoside transporter 
expression in IBD intestine remains unclear. Elevated levels of nucleoside 
transporters may trigger an influx of nucleosides, such as adenosine, and be 
responsible for inflammation of the tissue - similarly to the mechanism proposed for 
inflammatory lung diseases (Hirsh et al., 2007). In support of this, mRNA levels of 
nucleoside transporters are elevated in the inflamed tissues of IBD patients (Fig. 1 
and 2). This observation may also imply a role for pro-inflammatory cytokines in 
transcriptional regulation of nucleoside transporter genes in intestinal cells, as 
already reported in the context of liver parenchymal cells (Fernández-Veledo et al., 
2004) and macrophages (Soler et al., 2001). While we did not observe any changes 
in nucleoside transporter mRNA levels in patients taking standard therapies, it would 
be interesting to measure mRNA levels of nucleoside transporters in IBD patients 
taking anti-TNF-α medications, such as infliximab or adalimumab. 
 Another group of target genes exhibiting increased mRNA levels in IBD 
patients is the family of organic anion transporting polypeptides. In both terminal 
ileum and colon, we observed an increased mRNA expression of OATP2B1 and 
OATP4A1 in IBD patients. This elevation is correlated with the inflammatory status of 
the tissue in both intestinal regions, and is most significant in colon of UC patients 
(Fig. 2). It has been reported that the mRNA levels of murine hepatic Oatp2 are 
sensitive to pro-inflammatory signalling (Hartmann et al., 2002), but until now there 
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has been no clear indication that OATP transporters may be involved in the 
pathology of IBD in humans. 
 We also observed increased mRNA expression of PEPT1 in both regions of 
the intestine in IBD patients. This elevation was statistically significant in colon of 
both CD and UC patients and was correlated with the inflammation of the tissue. 
Elevated expression of PEPT1 has already been previously implicated in 
inflammation and the pathology of IBD (Vavricka et al., 2006). 
 The intestinal SLC mRNA levels are dysregulated in IBD patients, which may 
be linked to the inflammatory status of the affected tissue. Determining expression 
levels of SLC transporters in inflamed and non-inflamed intestine provides an 
indication about the role of inflammatory signalling cascades on regulation of SLC 
expression. While it is important to bear in mind that changes in mRNA levels may 
not fully correlate with such alterations in the corresponding protein levels, we believe 
that the expression levels of SLCs may help to assess the severity of the disease 
and/or serve as prognostic factor for patients taking certain medications and that this 
information may help to optimize drug therapies for IBD patients. 
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Figure legends 
 
Fig. 1. The changes in mRNA expression levels of SLCs in the inflamed tissues of 
CD patients. (A). The mRNA expression levels of ENT1, ENT2, but not OATP2B1 
and OATP4A1, are elevated in inflamed tissues of terminal ileum of all CD patients of 
the study. Mean values of mRNA expression levels are presented. Error bars indicate 
SD values. (B). Paired analysis of inflamed and non-inflamed tissues from the same 
patients shows a significant increase of ENT2, and OATP2B1, in terminal ileum. The 
mRNA expression levels in non-inflamed tissues were set to 1. (C). The mRNA 
expression levels of ENT1, ENT2, CNT2, OATP2B1, OATP4A1 and PEPT1 are 
increased in inflamed colon of CD patients. Averages of mRNA expression levels are 
presented. (D) Paired comparison of inflamed and non-inflamed tissues shows a 
significant increase in ENT2, CNT2, OATP2B1, OCTN1, and PEPT1 mRNA levels. 
The mRNA expression levels in non-inflamed tissues were set to 1. P value: * < 0.05; 
** <0.01; *** <0.001. Error bars indicate SD values. 
 
Fig. 2. The changes in mRNA expression levels of SLCs in the inflamed colon of UC 
patients. (A) The mRNA expression levels of ENT1, ENT2, CNT2, and OATP4A1, 
and PEPT1 are significantly higher in the inflamed tissues. mRNA levels of OCTN1 
and OCTN2 are not significantly changed. Mean values of mRNA expression levels 
are presented. Error bars indicate SD values. (B) Paired comparison of inflamed and 
non-inflamed tissues from the same patients shows a significant increase in mRNA 
levels of ENT1, ENT2, CNT2, OATP2B1, OATP4A1 and OCTN1. Elevation of mRNA 
levels of OCTN2 and PEPT1 is not significant. The mRNA expression levels in non-
inflamed tissues were set to 1. P value: * < 0.05; ** <0.01; *** <0.001. 
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Table 1. The characteristics of 15 solute carrier transporters investigated in this study. 
Full name Acronym SLC 
code 
Tissue 
expression 
Substrate 
specificity 
Reported/implicated 
association with 
inflammation in: 
Reported/ 
implicated 
association 
with IBD 
References 
Apical sodium-
dependent bile 
acid transporter 
ASBT SLC10A2 
Small intestine, 
biliary epithelium, 
kidney 
Bile acids Human colonic cell line Yes Jung et al., 2004; Neimark et al., 2006 
Concentrative 
nucleoside 
transporter 1 
CNT1 SLC28A1 
Jejunum, kidney, 
liver, small 
intestine, brain 
Nucleosides, 
nucleoside 
analogues 
Rat hepatocytes No Fernàndez-Veledo et al., 2004; Podgórska et al., 2005 
Concentrative 
nucleoside 
transporter  2 
CNT2 SLC28A2 
Kidney, liver, 
intestine, jejunum, 
heart, brain, 
Nucleosides, 
nucleoside 
analogues 
Human primary epithelial 
cells No 
Hirsh et al., 2007; Podgórska et al., 
2005 
Concentrative 
nucleoside 
transporter 3 
CNT3 SLC28A3 
Bone marrow, 
pancreas, trachea, 
mammary gland, 
placenta 
Nucleosides, 
nucleoside 
analogues 
Human primary epithelial 
cells No 
Hirsh et al., 2007; Podgórska et al., 
2005 
Equilibrative 
nucleoside 
transporter 1 
ENT1 SLC29A1 Ubiquitous 
Nucleosides, 
nucleoside 
analogues 
None No Podgórska et al., 2005; Santini et al., 2008 
Equilibrative 
nucleoside 
transporter 2 
ENT2 SLC29A2 Ubiquitous 
Nucleosides, 
nucleoside 
analogues 
None No Podgórska et al., 2005 
Organic anion 
transporter 2 OAT2 SLC22A7 
Liver, kidney, 
adipose tissue Organic anions None No Burckhardt et al., 2000 
Organic anion 
transporting 
polypeptide 1A2 
OATP1A2 SLCO1A2 Brain (endothelial cells), kidney, liver 
Bile salts, 
organic anions 
and cations 
None No Hagenbuch et al., 2004 
Organic anion 
transporting 
polypeptide 2B1 
OATP2B1 SLCO2B1 Liver, placenta E-3-S, DHEAS Human primary hepatocytes No 
Hagenbuch et al., 2004;  Lee Vee et al., 
2008 
Organic anion 
transporting 
polypeptide 4A1 
OATP4A1 SLCO4A1 Ubiquitous Taurocholate, prostaglandin None No Hagenbuch et al., 2004 
Organic cation 
transporter 1 OCT1 SLC22A1 Liver Organic cations None No 
Burckhardt et al., 2000; Koepsell et al., 
2007 
Organic 
cation/zwitterion 
transporter 1 
OCTN1 SLC22A4 
Kidney, intestine, 
heart, skeletal 
muscle, placenta 
Organic cations None Yes 
Cucchiara et al., 2007; Noble et al., 
2008; Russell et al., 2004; Silverberg et 
al., 2007; Waller et al., 2006 
Organic 
cation/zwitterion 
transporter 2 
OCTN2 SLC22A5 
Kidney, intestine, 
heart, skeletal 
muscle, placenta 
Organic cations, 
carnitine 
Experimental colitis in 
mice and rats Yes 
Cucchiara et al., 2007; D’Argenio et al., 
2006; Noble et al., 2008; Russell et al., 
2004; Shekhawat et al., 2007; 
Silverberg et al., 2007; Waller et al., 
2006 
Peptide 
transporter 1 PEPT1 SLC15A1 Intestine, kidney 
Di- and tri-
peptides 
Human intestinal cell 
lines Yes 
Dalmasso et al., 2008; Daniel et al., 
2004; Vavricka et al., 2006 
Serotonin 
transporter SERT SLC6A4 
Brain, small 
intestine Serotonin 
Experimental colitis in 
mice; human intestine-
derived cell line 
No Coates et al., 2006; Foley et al., 2007; Linden et al., 2005 
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Table 2. Summary of patients included in the study. 
 
 IBD control 
Number of patients (CD/UC) 102 (49/53) 23 
Number of biopsies (CD/UC) 193 (97/96) 43 
Males/Females/Unknown 40/61/1 7/16/0 
Average age (SD) 48 (15) 60 (10) 
Average BMI (SD) 24.9 (5.0) 24.0 (4.0) 
Number of patients on therapy 
• Steroids 
• Azathioprine 
• Mesalazine 
• None 
• Other 
 
28 
17 
29 
29 
36 
 
0 
0 
0 
19 
4 
Smokers/non-smokers/unknown 26/64/12 - 
Patients in remission 29 - 
Inflamed/non-inflamed (biopsies total) 73/120 - 
Inflamed/non-inflamed (paired biopsies) 53/53 - 
Patients excluded 0 0 
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Table 3. The relative mRNA expression levels of 15 SLC transporters. The expression level of the 
target genes in each sample was evaluated based on the ratio of cDNA copies of a target gene vs. 
cDNA copies of villin. Numbers represent mean values (±SD). Targets with detectable mRNA 
expression levels and statistical signifiacant changes are marked in bold (ns: not significant). 
 
Terminal ileum 
SLC Control CD p- value (vs control) UC 
p- value 
(vs control) 
p- value 
(CD vs UC) 
PEPT1 
OCNT1 
ASBT 
CNT2 
CNT1 
OCTN2 
SERT 
OATP2B1 
ENT2 
ENT1 
OCT1 
OATP4A1 
OATP1A2 
CNT3 
OAT2 
7.44 (±4.33) 
2.00 (±1.28) 
0.96 (±0.85) 
0.85 (±0.63) 
0.15 (±0.09) 
0.1 (±0.05) 
0.05 (±0.04) 
0.01 (±0.01) 
0.01 (±0.01) 
0.008 (±0.01) 
0.004 (±0.007) 
0.002 (±0.003) 
0.002 (±0.006) 
0.001 (±0.001) 
0.0009 (±0.002) 
10.02 (±6.39) 
2.32 (±1.39) 
0.12 (±0.12) 
0.76 (±0.57) 
0.25 (±0.15) 
0.02 (±0.01) 
0.16 (±0.09) 
0.07 (±0.07) 
0.04 (±0.03) 
0.02 (±0.02) 
0.003 (±0.002) 
0.01 (±0.009) 
0.00006 (±0.0001) 
0.003 (±0.004) 
0.001 (±0.002) 
ns 
ns 
< 0.001 
ns 
< 0.01 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
ns 
< 0.001 
- 
- 
- 
10.16 (±6.79) 
2.76 (±2.16) 
0.21 (±0.19) 
0.39 (±0.27) 
0.22 (±0.13) 
0.02 (±0.02) 
0.15 (±0.12) 
0.04 (±0.02) 
0.05 (±0.03) 
0.02 (±0.01) 
0.004 (±0.005) 
0.01 (±0.009) 
0.00005 (±0.00005) 
0.001 (±0.001) 
0.003 (±0.008) 
ns 
ns 
< 0.05 
ns 
ns 
< 0.001 
< 0.05 
< 0.05 
< 0.01 
< 0.05 
ns 
< 0.001 
- 
- 
- 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
- 
- 
- 
Colon 
SLC Control CD p- value (vs control) UC 
p- value 
(vs control) 
p- value 
(CD vs UC) 
OCTN1 
OCTN2 
PEPT1 
ENT2 
CNT2 
ENT1 
OATP2B1 
OATP4A1 
OCT1 
ASBT 
OAT2 
SERT 
CNT3 
CNT1 
OATP1A2 
0.53 (±0.53) 
0.26 (±0.14) 
0.18 (±0.23) 
0.09 (±0.11) 
0.05 (±0.05) 
0.02 (±0.02) 
0.01 (±0.01) 
0.01 (±0.01) 
0.01 (±0.01) 
0.007 (±0.008) 
0.003 (±0.006) 
0.002 (±0.003) 
0.001 (±0.001) 
0.001 (±0.001) 
0.0003 (±0.001) 
0.76 (±0.8) 
0.05 (±0.04) 
0.58 (±0.63) 
0.17 (±0.07) 
0.35 (±0.42) 
0.05 (±0.06) 
0.08 (±0.07) 
0.03 (±0.06) 
0.01 (±0.07) 
0.0002 (±0.0005) 
0.0008 (±0.001) 
0.002 (±0.004) 
0.002 (±0.004) 
0.001 (±0.0006) 
0.00006 (±0.0001) 
ns 
< 0.001 
< 0.05 
< 0.001 
< 0.001 
< 0.01 
< 0.001 
< 0.01 
ns 
< 0.001 
- 
- 
- 
- 
- 
0.91 (±0.78) 
0.04 (±0.05) 
0.67 (±1.14) 
0.2 (±0.17) 
0.6 (±0.79) 
0.07 (±0.07) 
0.13 (±0.13) 
0.08 (±0.11) 
0.008 (±0.008) 
0.0005 (±0.001) 
0.001 (±0.003) 
0.003 (±0.005) 
0.008 (±0.017) 
0.001 (±0.0006) 
0.00007 (±0.0001) 
< 0.05 
< 0.001 
ns 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
ns 
< 0.001 
- 
- 
- 
- 
- 
ns 
ns 
ns 
ns 
ns 
ns 
< 0.05 
< 0.05 
ns 
ns 
- 
- 
- 
- 
- 
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Table 4. Changes in the mRNA expression levels of SLCs in IBD patients on steroid therapy. 
Statistical significance was estimated using unpaired t-test with two tailed p-value. 
 
SLC Region Disease Group Fold change p-value 
OCTN2 
OCTN2 
ASBT 
OATP4A1 
OATP4A1 
OATP2B1 
ENT1 
 
Colon 
Colon 
Terminal ileum 
Colon 
Colon 
Colon 
Terminal ileum 
 
CD 
UC 
CD 
UC 
UC 
CD 
CD 
 
males 
males 
males 
females 
males 
females 
females 
 
2.88 
2.28 
-7.23 
1.99 
2.00 
-1.86 
-1.78 
 
0.0003 
0.0115 
0.0708 
0.1276 
0.1416 
0.144 
0.1494 
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